Wall Street analysts expect Radius Health, Inc. (NASDAQ:RDUS) to announce earnings per share (EPS) of ($1.35) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Radius Health’s earnings, with the lowest EPS estimate coming in at ($1.46) and the highest estimate coming in at ($1.24). Radius Health posted earnings of ($1.01) per share during the same quarter last year, which would suggest a negative year over year growth rate of 33.7%. The firm is expected to report its next earnings results after the market closes on Thursday, August 3rd.

According to Zacks, analysts expect that Radius Health will report full year earnings of ($4.99) per share for the current fiscal year, with EPS estimates ranging from ($5.74) to ($4.36). For the next fiscal year, analysts expect that the business will report earnings of ($3.71) per share, with EPS estimates ranging from ($5.38) to ($2.83). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Radius Health.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.18) by $0.14. During the same period in the previous year, the company posted ($0.94) EPS.

Several research analysts have recently weighed in on RDUS shares. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target (down previously from $71.00) on shares of Radius Health in a report on Friday, March 24th. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Cantor Fitzgerald restated a “buy” rating and set a $65.00 target price on shares of Radius Health in a report on Friday, April 28th. Canaccord Genuity restated a “buy” rating on shares of Radius Health in a report on Friday, April 28th. Finally, Maxim Group restated a “sell” rating on shares of Radius Health in a report on Monday, May 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $56.83.

In other Radius Health news, major shareholder Growth N. V. Biotech purchased 150,000 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $5,308,500.00. Following the completion of the purchase, the insider now owns 4,690,399 shares of the company’s stock, valued at approximately $165,993,220.61. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Growth N. V. Biotech purchased 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was acquired at an average price of $33.91 per share, for a total transaction of $2,543,250.00. Following the completion of the purchase, the insider now directly owns 4,765,399 shares of the company’s stock, valued at approximately $161,594,680.09. The disclosure for this purchase can be found here. Insiders have acquired 498,400 shares of company stock worth $17,411,288 over the last ninety days. Insiders own 15.00% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. acquired a new position in Radius Health during the first quarter valued at approximately $105,000. Envestnet Asset Management Inc. increased its position in Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 46 shares during the period. Russell Investments Group Ltd. acquired a new position in Radius Health during the fourth quarter valued at approximately $197,000. Karp Capital Management Corp acquired a new position in Radius Health during the first quarter valued at approximately $217,000. Finally, FNY Partners Fund LP increased its position in Radius Health by 40.5% in the first quarter. FNY Partners Fund LP now owns 5,900 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 1,700 shares during the period.

Shares of Radius Health (NASDAQ RDUS) traded up 1.51% during mid-day trading on Wednesday, reaching $42.46. 925,784 shares of the company were exchanged. The stock’s market capitalization is $1.84 billion. Radius Health has a 12 month low of $31.58 and a 12 month high of $59.88. The firm has a 50-day moving average price of $42.61 and a 200 day moving average price of $40.56.

TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/07/19/brokerages-anticipate-radius-health-inc-nasdaqrdus-will-post-earnings-of-1-35-per-share.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.